公开(公告)号：EP1353915A2

公开(公告)日：2003-10-22

申请号：EP02715919.3

申请日：2002-01-15

申请人： AstraZeneca AB

发明人： CHAPDELAINE, Marc,AstraZeneca Wilmington ,  DAVENPORT, Timothy,AstraZeneca Wilmington ,  HAEBERLEIN, Markus ,  HORCHLER, Carey,AstraZeneca Wilmington ,  MCCAULEY, John,AstraZeneca Wilmington ,  PIERSON, Edward,AstraZeneca Wilmington ,  SOHN, Daniel

IPC分类号： C07D311/74 ,  A61K31/5377

CPC分类号： C07D231/12 ,  C07D215/50 ,  C07D233/56 ,  C07D249/08 ,  C07D311/24 ,  C07D311/58 ,  C07D401/04 ,  C07D401/12 ,  C07D405/04 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12

摘要： Provided herein is a compound represented by the Formula (I) wherein said compounds are useful for the treatment of migraine. Also provided are processes for the preparation of compounds of Formula (I) and intermediates.

公开(公告)号：EP1451158A1

公开(公告)日：2004-09-01

申请号：EP02782061.2

申请日：2002-11-01

申请人： AstraZeneca AB

发明人： CHAPDELAINE, Marc,AstraZeneca Wilmington ,  DAVENPORT, Timothy ,  HAEBERLEIN, Markus,AstraZeneca R & D Södertälje ,  HORCHLER, Carey,AstraZeneca Wilmington ,  MCCAULEY, John,AstraZeneca Wilmington ,  PIERSON, Edward,AstraZeneca Wilmington ,  SOHN, Daniel,AstraZeneca R & D Södertälje

IPC分类号： C07D215/42 ,  C07D215/48 ,  C07D215/233 ,  C07D207/14 ,  C07D241/04 ,  C07D243/08 ,  C07D265/30 ,  C07D401/14 ,  C07D413/14 ,  A61K31/496 ,  A61K31/551 ,  A61K31/5377 ,  A61P1/00 ,  A61P3/04 ,  A61P5/00 ,  A61P15/00 ,  A61P21/02 ,  A61P43/00

CPC分类号： C07D215/233 ,  C07D215/42 ,  C07D311/24 ,  C07D401/04 ,  C07D401/12 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12 ,  Y02E60/324

摘要： Provided herein is a compound having the formula (I), (R2 is typically a tertiary nitrogen atom, being either alkyl-substituted or member of a heterocyclic ring; R7 is typically a monocyclic or bicyclic aromatic ring or a heterocyclic ring) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.

公开(公告)号：EP1353913A2

公开(公告)日：2003-10-22

申请号：EP02729622.7

申请日：2002-01-15

申请人： AstraZeneca AB

发明人： CHAPDELAINE, Marc,AstraZeneca Wilmington ,  DAVENPORT, Timothy,AstraZeneca Wilmington ,  HAEBERLEIN, Markus ,  HORCHLER, Carey,AstraZeneca Wilmington ,  MCCAULEY, John,AstraZeneca Wilmington ,  PIERSON, Edward,AstraZeneca Wilmington ,  SOHN, Daniel

IPC分类号： C07D311/24 ,  C07D311/74 ,  C07D405/14 ,  C07D417/14 ,  C07D215/233 ,  C07D215/48 ,  C07D401/14 ,  A61K31/5377 ,  A61K31/497

CPC分类号： C07D231/12 ,  A61K31/495 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  C07D215/50 ,  C07D233/56 ,  C07D249/08 ,  C07D311/24 ,  C07D311/58 ,  C07D401/04 ,  C07D401/12 ,  C07D405/06 ,  C07D405/12 ,  C07D405/14 ,  C07D413/06 ,  C07D417/12

摘要： Provided herein is a compound having the formula (I) wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1B and 5HT1D antagonists.